“This trial emphasizes the importance of germline and somatic testing in patients with metastatic prostate cancer at the time of diagnosis; homologous recombination repair mutations have been ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

“The findings from Destiny-Breast09 represent a new first line standard treatment option for HER-2 positive metastatic breast cancer. The duration of therapy can now be measured in years and gives us ...

Main Takeaway Perioperative treatment with durvalumab (Imfinzi) and chemotherapy led to longer survival without cancer recurrence, progression or treatment-related complications for patients with ...

“This early but promising observational study suggests a powerful synergy: patients with stage III colon cancer who embraced anti-inflammatory foods and exercised regularly showed the best overall ...

“The early switch approach of the SERENA-6 clinical trial resulted in a 56% reduction in the risk of disease progression or death for patients who switched to treatment with camizestrant, allowing ...

“This study shows that sacituzumab govitecan, when combined with pembrolizumab as an initial treatment for patients with metastatic triple-negative breast cancer, delivers superior disease control and ...

“Trastuzumab deruxtecan is approved for patients with metastatic HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma who received a prior trastuzumab-based regimen based on ...

“This study will change the standard of care for the subset of patients with deficient DNA mismatch repair colon cancer by incorporating atezolizumab to standard of care FOLFOX chemotherapy in the ...

"These early, interim results from a promising prospective, randomized study evaluating the role of adjuvant chemotherapy in patients with stage IA-IIA non-small cell lung cancer identified as ...

Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information ...

Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information ...